company background image
YMAB

Y-mAbs Therapeutics NasdaqGS:YMAB Stock Report

Last Price

US$4.19

Market Cap

US$183.0m

7D

2.7%

1Y

-75.6%

Updated

27 Nov, 2022

Data

Company Financials +
YMAB fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

YMAB Stock Overview

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States.

Y-mAbs Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Y-mAbs Therapeutics
Historical stock prices
Current Share PriceUS$4.19
52 Week HighUS$20.48
52 Week LowUS$2.94
Beta0.73
1 Month Change-53.08%
3 Month Change-72.97%
1 Year Change-75.57%
3 Year Change-87.59%
5 Year Changen/a
Change since IPO-82.54%

Recent News & Updates

Recent updates

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Aug 13
Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

May 12
Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

Y-mAbs Therapeutics (NASDAQ:YMAB) Is In A Good Position To Deliver On Growth Plans

Dec 09
Y-mAbs Therapeutics (NASDAQ:YMAB) Is In A Good Position To Deliver On Growth Plans

Brokers Are Upgrading Their Views On Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) With These New Forecasts

Aug 11
Brokers Are Upgrading Their Views On Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) With These New Forecasts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 09
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Here's Why We're Not Too Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation

Jul 07
Here's Why We're Not Too Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation

These Analysts Just Made A Massive Downgrade To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) EPS Forecasts

Mar 01
These Analysts Just Made A Massive Downgrade To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) EPS Forecasts

Here's Why We're Not Too Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation

Jan 28
Here's Why We're Not Too Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation

Have Insiders Sold Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Recently?

Dec 06
Have Insiders Sold Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Recently?

Who Has Been Selling Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares?

Nov 18
Who Has Been Selling Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares?

Shareholder Returns

YMABUS BiotechsUS Market
7D2.7%0.4%1.3%
1Y-75.6%-14.4%-18.5%

Return vs Industry: YMAB underperformed the US Biotechs industry which returned -14.4% over the past year.

Return vs Market: YMAB underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is YMAB's price volatile compared to industry and market?
YMAB volatility
YMAB Average Weekly Movement22.6%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: YMAB is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.

Volatility Over Time: YMAB's weekly volatility has increased from 16% to 23% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015148Thomas Gadhttps://www.ymabs.com

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Y-mAbs Therapeutics, Inc. Fundamentals Summary

How do Y-mAbs Therapeutics's earnings and revenue compare to its market cap?
YMAB fundamental statistics
Market CapUS$182.97m
Earnings (TTM)-US$133.62m
Revenue (TTM)US$43.42m

4.2x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
YMAB income statement (TTM)
RevenueUS$43.42m
Cost of RevenueUS$7.01m
Gross ProfitUS$36.41m
Other ExpensesUS$170.03m
Earnings-US$133.62m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.06
Gross Margin83.86%
Net Profit Margin-307.75%
Debt/Equity Ratio0%

How did YMAB perform over the long term?

See historical performance and comparison